Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1Genitourinary 1

Conditions

Urinary Bladder Neoplasms 1Sarcoma 1Endometrial Neoplasms 1

Interventions

pembrolizumab 3NVP-BKM120 2Bevacizumab 2trastuzumab duocarmazine 1talazoparib 1sitravatinib 1ponatinib 1niraparib 1mirvetuximab soravtansine 1lenvatinib 1dostarlimab 1dactolisib 1bemarituzumab 1Trastuzumab 1Taxes 1TAS-116 1Sevoflurane 1Radiotherapy 1Propofol 1Proflavine 1Polymerase Chain Reaction 1Paclitaxel 1PM 01183 1Methods 1Metformin 1Megestrol Acetate 1Magnetic Resonance Spectroscopy 1Letrozole 1Interviews as Topic 1Gene Expression Profiling 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Endometrial Neoplasms × TAS-116 × Clear all
NCT05655598 2024-09-19

TAS-116 Plus Palbociclib in Breast and Rb-null Cancer

Brown University

Phase 1 Withdrawn
GenitourinaryGynecologicSarcoma

Urinary Bladder Neoplasms, Sarcoma, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡